By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Ensemble Therapeutics Corporation 

99 Erie Street

Cambridge  Massachusetts  02139-4535  U.S.A.
Phone: 617-492-6977 Fax: 617-492-6689



Company News
In High Demand: Ensemble Therapeutics Corporation Picks Novartis AG (NVS) to Develop Oral, Mid-Sized Inflammation Drugs 8/6/2013 7:37:15 AM
Roaring Alexion Pharmaceuticals Inc. (ALXN) Reaches Out to Ensemble Therapeutics Corporation to Fight Ultra-Rare Disorders 7/18/2013 8:57:57 AM
Ensemble Therapeutics Corporation to Present Data on IL-17A Inhibitors that are Novel, Oral Macrocycles Against Previously Undruggable Target 4/1/2013 10:03:11 AM
Ensemble Therapeutics Corporation Presents Oral Efficacy of First-in-Class Small Molecule Targeting IL-17 for Inflammation in Preclinical Studies 11/12/2012 9:45:46 AM
Ensemble Therapeutics Corporation, Boehringer Ingelheim Corporation Ink $186 Milliion Macrocycle Drug Pact 11/1/2012 7:53:30 AM
Ensemble Therapeutics Corporation to Present at 2012 American College of Rheumatology Annual Meeting 10/29/2012 6:56:10 AM
Ensemble Therapeutics Corporation and Genentech (RHHBY) Initiate Collaboration to Discover Macrocyclic Drug Candidates 5/29/2012 11:14:45 AM
Ensemble Therapeutics Corporation Advances Macrocycle IL-17 Antagonist Program: Reports First Known Small Molecule Inhibitors of Important Autoimmune Target 1/5/2012 2:07:13 PM
Ensemble Therapeutics Corporation Extends Macrocycle Drug Discovery Alliance with Bristol-Myers Squibb Company (BMY) 1/5/2012 6:53:46 AM
Ensemble Therapeutics Corporation Receives Two Notices of Allowance for Fundamental Patents to DNA-Programmed Chemistry Process for Novel Macrocycle Therapeutics 7/6/2011 10:57:13 AM